AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2198807 — intervention group
Group type: COMPARATOR
Intervention: Monovalent mumps vaccine (Hoshino strain)
Number of subjects: 1369
Study 343726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 9
Study 343726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 343726 — intervention group
Group type: COMPARATOR
Intervention: Laboratory assessments
Number of subjects: 9
Study 31184922 — intervention group
Group type: EXPERIMENTAL
Intervention: mDiab app with weekly coach calls for 12 weeks
Number of subjects: 270
Study 31184922 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 270
Study 31184922 — intervention group
Group type: EXPERIMENTAL
Intervention: mDiab app with video lessons
Number of subjects: 270
Study 31184922 — intervention group
Group type: EXPERIMENTAL
Intervention: mDiab app
Number of subjects: 270
Study 28503774 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 39
Study 28503774 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 39
Study 26667737 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program based on balance and lower body strength for 24 weeks
Number of subjects: 56
Study 26667737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 23127542 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 4
Study 23127542 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 4
Study 21786029 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality management acute pain program (certified by TÜV Rheinland)
Number of subjects: 27
Study 21786029 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the QUIPS project
Number of subjects: 27
Study 21786029 — intervention group
Group type: COMPARATOR
Intervention: Control group with no involvement in either concept
Number of subjects: 27
Study 19199362 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 23
Study 19199362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17147832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored energy balance programme for recent retirees, low-intensity, duration of one year.
Number of subjects: 0
Study 17147832 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of anthropometry, physical activity, energy intake, and related psychosocial determinants.
Number of subjects: 0
Study 15331528 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (0.1 mU/kg body wt as bolus)
Number of subjects: 27
Study 15331528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11546713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg x kg(‐1) urapidil
Number of subjects: 150
Study 11546713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg x kg(‐1) urapidil
Number of subjects: 150
Study 11546713 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg x kg(‐1) urapidil
Number of subjects: 150
Study 11546713 — intervention group
Group type: COMPARATOR
Intervention: 3 microg x kg(‐1) clonidine (positive control group)
Number of subjects: 150
Study 11546713 — intervention group
Group type: COMPARATOR
Intervention: saline 0.9% (negative control group)
Number of subjects: 150
Study 9100580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose (Study 1)
Number of subjects: 47
Study 9100580 — intervention group
Group type: COMPARATOR
Intervention: Water (Study 1)
Number of subjects: 47
Study 9100580 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose (Study 2)
Number of subjects: 47
Study 9100580 — intervention group
Group type: COMPARATOR
Intervention: Water (Study 2)
Number of subjects: 47
Study 7794122 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (2-7 mg daily)
Number of subjects: 40
Study 2968309 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) infusion (125 ng/kg bolus followed by a 30-minute infusion at 25 ng/kg/min)
Number of subjects: 16
Study 2968309 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (time-control)
Number of subjects: 16
Study 29958220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 µg/kg IV bolus in 10 minutes, followed by 0.5-1.0 µg/kg/h)
Number of subjects: 60
Study 29958220 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.5 µg/kg IV bolus in 10 minutes, followed by 0.05-0.25 µg/kg/min)
Number of subjects: 60
Study 29958220 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 29958220 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 60
Study 28370407 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS804 (5, 10, and 20 mg/kg, three escalating doses each separated by 2 weeks)
Number of subjects: 14
Study 28370407 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 14
Study 25923596 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 137
Study 25923596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 23171089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.5mg for FD, 1mg for controls)
Number of subjects: 34
Study 23171089 — intervention group
Group type: COMPARATOR
Intervention: Capsaicin
Number of subjects: 34
Study 22290681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural block (CSEB)
Number of subjects: 40
Study 22290681 — intervention group
Group type: COMPARATOR
Intervention: Spinal block (SB)
Number of subjects: 40
Study 19453322 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway
Number of subjects: 50
Study 19453322 — intervention group
Group type: COMPARATOR
Intervention: classic laryngeal mask airway (cLMA)
Number of subjects: 50
Study 17078446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture; specific dosage and duration not mentioned.
Number of subjects: 0
Study 17078446 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy subjects; control group not explicitly mentioned.
Number of subjects: 0
Study 15154919 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment with one of three sealers chosen at random
Number of subjects: 498
Study 15154919 — intervention group
Group type: COMPARATOR
Intervention: Conventional success/failure assessment (END2)
Number of subjects: 498
Study 11316108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol 2.5 mg with ipratropium 0.5 mg and placebo inhalers (MDI) with spacer
Number of subjects: 19
Study 11316108 — intervention group
Group type: COMPARATOR
Intervention: Placebo nebules and inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Number of subjects: 19
Study 11316108 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol 400 microg with ipratropium 80 microg via MDI with spacer
Number of subjects: 19
Study 9530619 — intervention group
Group type: EXPERIMENTAL
Intervention: MOM HA (whey hydrolysate formula)
Number of subjects: 25
Study 9530619 — intervention group
Group type: COMPARATOR
Intervention: COW (cow's milk)
Number of subjects: 25
Study 8513853 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac
Number of subjects: 18
Study 8513853 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg b.i.d. isradipine
Number of subjects: 18
Study 8513853 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of diclofenac and isradipine
Number of subjects: 18
Study 8513853 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 18
Study 3812056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 0
Study 3812056 — intervention group
Group type: COMPARATOR
Intervention: Control (non-smoking)
Number of subjects: 0
Study 28992127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 749
Study 28992127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 26603742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg fast-release aspirin
Number of subjects: 0
Study 26603742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol
Number of subjects: 0
Study 26603742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25304478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungowned
Number of subjects: 214
Study 25304478 — intervention group
Group type: COMPARATOR
Intervention: Gowned
Number of subjects: 214
Study 24189569 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help version of cognitive behavioral therapy (shCBT)
Number of subjects: 48
Study 24189569 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 48
Study 24189569 — intervention group
Group type: EXPERIMENTAL
Intervention: shCBT
Number of subjects: 48
Study 24189569 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 48
Study 21393063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1.5 g/day for 24 months
Number of subjects: 277
Study 21393063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 21393063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 277
Study 18443265 — intervention group
Group type: EXPERIMENTAL
Intervention: Active normal-weight individuals
Number of subjects: 38987
Study 18443265 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of walking
Number of subjects: 38987
Study 17194233 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg(‐1))
Number of subjects: 16
Study 17194233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12707479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy plus routine care
Number of subjects: 0
Study 12707479 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 0
Study 11028832 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 418
Study 11028832 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tropisetron
Number of subjects: 418
Study 11028832 — intervention group
Group type: COMPARATOR
Intervention: 15 mg tropisetron
Number of subjects: 418
Study 11028832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 8864090 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy
Number of subjects: 53
Study 8864090 — intervention group
Group type: COMPARATOR
Intervention: Open tension-free Lichtenstein repair
Number of subjects: 53
Study 2056905 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate (CC) 7.0 mg of anhydrous caffeine.kg‐1 body weight
Number of subjects: 10
Study 2056905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 7171533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-methoxyl pectin (15 g)
Number of subjects: 10
Study 7171533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-methoxyl pectin (15 g)
Number of subjects: 10
Study 7171533 — intervention group
Group type: COMPARATOR
Intervention: Control (no pectin)
Number of subjects: 10
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: TEG
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTEM-FIBTEM
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: rTEG-FF
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTEM
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: rTEG
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: EXTEM Li30
Number of subjects: 2287
Study 29794847 — intervention group
Group type: EXPERIMENTAL
Intervention: rTEG Ly30
Number of subjects: 2287
Study 28010246 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent rAT or rLukS-PV dosages of 10, 25, 50, and 100 μg; bivalent rAT:rLukS dosages of 10:10, 25:25, and 50:50 μg; alum or saline placebo
Number of subjects: 176
Study 28010246 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent and bivalent rAT dosages
Number of subjects: 176
Study 28010246 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg monovalent or bivalent rAT and rLukS-PV dose
Number of subjects: 176
Study 28010246 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of the vaccine
Number of subjects: 176
Study 28010246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum or saline)
Number of subjects: 176
Study 25005011 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS training curriculum
Number of subjects: 30
Study 25005011 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS training curriculum (group A, tested after 4 weeks)
Number of subjects: 30
Study 25005011 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS training curriculum (group B, tested after 12 weeks)
Number of subjects: 30
Study 25005011 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A and group B
Number of subjects: 30
Study 24508897 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of tenofovir alafenamide
Number of subjects: 0
Study 24508897 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of tenofovir alafenamide
Number of subjects: 0
Study 24508897 — intervention group
Group type: COMPARATOR
Intervention: 300 mg of tenofovir disoproxil fumarate
Number of subjects: 0
Study 22020082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 18
Study 22020082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19758519 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP-BD study
Number of subjects: 0
Study 19758519 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Trials Network (BTN)
Number of subjects: 0
Study 17827369 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 27
Study 15042669 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (paclitaxel followed by combined 5-fluorouracil, doxorubicin, and cyclophosphamide)
Number of subjects: 240
Study 15042669 — intervention group
Group type: COMPARATOR
Intervention: Primary surgical management (control group)
Number of subjects: 240
Study 15042669 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 240
Study 11180038 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone
Number of subjects: 101
Study 11180038 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 101
Study 9621991 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid therapy (ACT) with dexamethasone
Number of subjects: 103
Study 9621991 — intervention group
Group type: COMPARATOR
Intervention: Non-ACT group (no antenatal corticosteroid therapy)
Number of subjects: 103
Study 9621991 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment of the mother
Number of subjects: 103
Study 9621991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolytic treatment of the mother
Number of subjects: 103
Study 8165968 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens implantation through a 3.2 mm incision
Number of subjects: 150
Study 8165968 — intervention group
Group type: COMPARATOR
Intervention: Polymethylmethacrylate intraocular lens implantation through a 5.5 mm incision
Number of subjects: 150
Study 3357663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraumbilical oxytocin (10 U diluted to 20 mL in normal saline)
Number of subjects: 50
Study 3357663 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (20 mL)
Number of subjects: 50
Study 29807936 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Paramedicine at Clinic (CP@clinic) for 1 year
Number of subjects: 1092
Study 29807936 — intervention group
Group type: COMPARATOR
Intervention: Usual health care
Number of subjects: 1092
Study 27911016 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab 300 mg
Number of subjects: 0
Study 27911016 — intervention group
Group type: COMPARATOR
Intervention: omalizumab (75, 150 or 300 mg)
Number of subjects: 0
Study 26720473 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized heterochromatic flicker photometry (Densitometer)
Number of subjects: 117
Study 26720473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-wavelength fundus autofluorescence (Spectralis)
Number of subjects: 117
Study 26720473 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices (Densitometer and Spectralis)
Number of subjects: 117
Study 23398390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (smoking cessation programme)
Number of subjects: 161
Study 23398390 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 161
Study 23398390 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 161
Study 21509050 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC) at baseline
Number of subjects: 1675
Study 21509050 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in waist circumference (WC) from baseline to follow-up
Number of subjects: 1675
Study 21509050 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) at baseline
Number of subjects: 1675
Study 21509050 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in body mass index (BMI) from baseline to follow-up
Number of subjects: 1675
Study 19090310 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of alkalinized lidocaine into the ETT cuff at intubation
Number of subjects: 160
Study 19090310 — intervention group
Group type: COMPARATOR
Intervention: Injection of local anesthetic into the LITA tube
Number of subjects: 160
Study 16773350 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 16773350 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 12818462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hormone replacement therapy (LD‐HRT) with conjugated equine estrogens (CEE; 0.3 mg) and different progestins (2.5 mg medroxyprogesterone acetate, 5 mg dydrogesterone, 2.5 mg nomegestrol)
Number of subjects: 63
Study 12818462 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (1 g per day)
Number of subjects: 63
Study 10969300 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 5 min before surgery
Number of subjects: 113
Study 10969300 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 10 min before surgery
Number of subjects: 113
Study 10969300 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) administered 20 min before surgery
Number of subjects: 113
Study 10969300 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 15 min before surgery
Number of subjects: 113
Study 8725758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial resection
Number of subjects: 0
Study 8725758 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal hysterectomy
Number of subjects: 0
Study 14621765 — intervention group
Group type: EXPERIMENTAL
Intervention: BT 563 (new monoclonal IL-2R antibody)
Number of subjects: 0
Study 14621765 — intervention group
Group type: COMPARATOR
Intervention: ATG (historical control)
Number of subjects: 0
Study 3881920 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O of CPAP
Number of subjects: 40
Study 3881920 — intervention group
Group type: COMPARATOR
Intervention: Ambient airway pressure breathing (Control)
Number of subjects: 40
Study 30869649 — intervention group
Group type: EXPERIMENTAL
Intervention: Health‐E You app (mHealth intervention)
Number of subjects: 18
Study 27599712 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) techniques
Number of subjects: 8
Study 26355978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (0.5 mg/kg) and acetaminophen (15 mg/kg)
Number of subjects: 50
Study 26355978 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen (10 mg/kg) and acetaminophen (15 mg/kg)
Number of subjects: 50
Study 26355978 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen and acetaminophen
Number of subjects: 50
Study 24028669 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 1577
Study 24028669 — intervention group
Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1577
Study 20923377 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC)
Number of subjects: 172
Study 20923377 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation method (STD)
Number of subjects: 172
Study 19811166 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) group
Number of subjects: 85
Study 19811166 — intervention group
Group type: COMPARATOR
Intervention: Lecture group
Number of subjects: 85
Study 16849414 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg)
Number of subjects: 51
Study 14663318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m HMPAO WBC imaging
Number of subjects: 34
Study 11003974 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 14
Study 11003974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8769685 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium (10-15 mg/day for an average of 10.2 weeks)
Number of subjects: 28
Study 8769685 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (5-10 mg/day for an average of 13.9 weeks)
Number of subjects: 28
Study 8769685 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 28
Study 1576841 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (40 sessions over 90 days; specialized equipment)
Number of subjects: 25
Study 1576841 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients completed the study)
Number of subjects: 25
Study 4073085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus clavulanic acid (3 g every four hours)
Number of subjects: 47